公开(公告)号：US20100125058A1

公开(公告)日：2010-05-20

申请号：US12614485

申请日：2009-11-09

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Eric Mertz ,  Sung-Sau So ,  Hong Ying Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Eric Mertz ,  Sung-Sau So ,  Hong Ying Yun ,  Zhenshan Zhang

IPC分类号： A61K31/397 ,  A61K31/44 ,  C07D211/72 ,  A61K31/19 ,  C07C315/00 ,  C07D241/04 ,  A61K31/497 ,  C07D205/00

CPC分类号： C07D213/71 ,  C07C255/54 ,  C07C311/29 ,  C07C317/22 ,  C07C317/36 ,  C07C317/44 ,  C07C317/46 ,  C07C323/65 ,  C07C2601/02 ,  C07C2601/08 ,  C07D211/38 ,  C07D295/26 ,  C07D491/10

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中W，X，Y和R 1 -R 7在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症，例如哮喘。

公开(公告)号：US20100125061A1

公开(公告)日：2010-05-20

申请号：US12614497

申请日：2009-11-09

申请人： Fariborz Firooznia ,  Tai-An Lin ,  Sung-Sau So ,  Baoxia Wang ,  Hong Ying Yun

发明人： Fariborz Firooznia ,  Tai-An Lin ,  Sung-Sau So ,  Baoxia Wang ,  Hong Ying Yun

IPC分类号： A61K31/495 ,  C07D241/04 ,  C07D401/04 ,  A61K31/496 ,  A61K31/397 ,  A61P37/08

CPC分类号： C07D295/192 ,  C07D213/74 ,  C07D239/42 ,  C07D295/18 ,  C07D401/12 ,  C07D487/10

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1-R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中X，Q和R 1 -R 3在详细描述和权利要求书中定义。 本发明还涉及式Z化合物及其药学上可接受的盐和酯，其中R1-R3在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I和Z化合物的方法以及含有这些化合物的药物组合物。 式I和Z的化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症如哮喘。